Byrne Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$314K Sell
2,485
-20
-0.8% -$2.63K 0.17% 101
2026
Q1
$349K Sell
2,505
-55
-2% -$7.7K 0.2% 91
2025
Q4
$314K Buy
+2,560
New +$311K 0.17% 99
2025
Q3
Sell
-2,720
Closed -$309K 93
2025
Q2
$302K Buy
+2,720
New +$289K 0.2% 85
2025
Q1
Sell
-3,230
Closed -$333K 83
2024
Q4
$298K Sell
3,230
-290
-8% -$26.1K 0.21% 86
2024
Q3
$295K Buy
+3,520
New +$269K 0.2% 92
2024
Q2
Sell
-12,205
Closed -$814K 98
2024
Q1
$894K Buy
+12,205
New +$939K 0.62% 53
2023
Q4
Hold
0
42
2023
Q3
Hold
0
42
2023
Q2
Sell
-13,027
Closed -$1.04M 44
2023
Q1
$1.08M Sell
13,027
-605
-4% -$50.1K 0.77% 36
2022
Q4
$1.17M Sell
13,632
-1,540
-10% -$122K 0.85% 30
2022
Q3
$936K Sell
15,172
-205
-1% -$12.9K 0.72% 40
2022
Q2
$950K Buy
15,377
+250
+2% +$15.5K 0.7% 46
2022
Q1
$899K Buy
15,127
+2,775
+22% +$177K 0.56% 58
2021
Q4
$897K Buy
+12,352
New +$851K 0.58% 52

Other funds holding GILD

Byrne Asset Management's GILD Position: Q2 2026 in Review

Byrne Asset Management reduced its Gilead Sciences (GILD) stake by 0.8% in Q2 2026, selling an estimated $2.63K and leaving 2,485 shares worth $314K. The position accounts for 0.17% of the portfolio, ranked #101.

Byrne Asset Management first reported a position in GILD in Q4 2021 and has held it in 13 quarters since. The position peaked at $1.17M in Q4 2022. 361 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Byrne Asset Management held 2,485 shares of Gilead Sciences worth $314K as of Q2 2026.
  • Byrne Asset Management sold 20 Gilead Sciences shares in Q2 2026, an estimated $2.63K.
  • Gilead Sciences made up 0.17% of Byrne Asset Management's portfolio in Q2 2026, its #101 holding.
  • Byrne Asset Management first reported a position in Gilead Sciences in Q4 2021 and has held it in 13 quarters since.
  • Byrne Asset Management's Gilead Sciences position peaked at $1.17M in Q4 2022.
  • 361 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Byrne Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.